Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy

BACKGROUND: Patients with locally advanced, unresectable, non‐small cell lung cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) benefit from durvalumab consolidation therapy. However, predictive factors for early relapse during durvalumab maintenance have not yet been iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Jung Hyun, Yeo, Chang Dong, Park, Chan Kwon, Kim, Sung Kyoung, Kim, Ju Sang, Kim, Yong Hyun, Kim, Jin Woo, Kim, Seung Joon, Lee, Sang Haak, Kang, Hye Seon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493476/
https://www.ncbi.nlm.nih.gov/pubmed/37519059
http://dx.doi.org/10.1111/1759-7714.15050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493476/
https://www.ncbi.nlm.nih.gov/pubmed/37519059
http://dx.doi.org/10.1111/1759-7714.15050

Ejemplares similares